Warning: The NCBI web site requires JavaScript to function. more...
A comparison of missing data methods for hypothesis tests of the treatment effect in substance abuse clinical trials: a Monte-Carlo simulation study.
Hedden SL, Woolson RF, Malcolm RJ.
Subst Abuse Treat Prev Policy. 2008 Jun 3;3:13.
Related citations
The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials.
Hedden SL, Woolson RF, Carter RE, Palesch Y, Upadhyaya HP, Malcolm RJ.
J Subst Abuse Treat. 2009 Jul;37(1):54-63. Epub 2008 Nov 13.
A simulation study of estimators for rates of change in longitudinal studies with attrition.
Wang-Clow F, Lange M, Laird NM, Ware JH.
Stat Med. 1995 Feb 15;14(3):283-97.
Assessing missing data assumptions in longitudinal studies: an example using a smoking cessation trial.
Yang X, Shoptaw S.
Drug Alcohol Depend. 2005 Mar 7;77(3):213-25.
The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA.
Mallinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ.
Clin Trials. 2004;1(6):477-89.
Randomization in substance abuse clinical trials.
Subst Abuse Treat Prev Policy. 2006 Feb 6;1:6. Review.
Clinical trial optimization: Monte Carlo simulation Markov model for planning clinical trials recruitment.
Abbas I, Rovira J, Casanovas J.
Contemp Clin Trials. 2007 May;28(3):220-31. Epub 2006 Aug 10.
Testing for robustness in Monte Carlo studies.
Serlin RC.
Psychol Methods. 2000 Jun;5(2):230-40.
Identifying the types of missingness in quality of life data from clinical trials.
Curran D, Bacchi M, Schmitz SF, Molenberghs G, Sylvester RJ.
Stat Med. 1998 Mar 15-Apr 15;17(5-7):739-56. Review.
Test for interaction between treatment and stratum with ordinal responses.
Uesaka H.
Biometrics. 1993 Mar;49(1):123-9.
Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.
Oden NL, VanVeldhuisen PC, Wakim PG, Trivedi MH, Somoza E, Lewis D.
Am J Drug Alcohol Abuse. 2011 Sep;37(5):350-7.
Exemplary data: sample size and power in the design of event-time clinical trials.
Goldman AI, Hillman DW.
Control Clin Trials. 1992 Aug;13(4):256-71.
Power analyses for longitudinal study designs with missing data.
Tu XM, Zhang J, Kowalski J, Shults J, Feng C, Sun W, Tang W.
Stat Med. 2007 Jul 10;26(15):2958-81.
Imputation methods for missing outcome data in meta-analysis of clinical trials.
Higgins JP, White IR, Wood AM.
Clin Trials. 2008;5(3):225-39.
An overview of practical approaches for handling missing data in clinical trials.
DeSouza CM, Legedza AT, Sankoh AJ.
J Biopharm Stat. 2009 Nov;19(6):1055-73. Review.
Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases.
Unnebrink K, Windeler J.
Stat Med. 2001 Dec 30;20(24):3931-46.
Design and analysis of group sequential logrank tests in maximum duration versus information trials.
Kim K, Boucher H, Tsiatis AA.
Biometrics. 1995 Sep;51(3):988-1000.
Weibull prediction of event times in clinical trials.
Ying GS, Heitjan DF.
Pharm Stat. 2008 Apr-Jun;7(2):107-20.
Practical usage of O'Brien's OLS and GLS statistics in clinical trials.
Dallow NS, Leonov SL, Roger JH.
Pharm Stat. 2008 Jan-Mar;7(1):53-68.
Sequential analysis of latent variables using mixed-effect latent variable models: Impact of non-informative and informative missing data.
Sébille V, Hardouin JB, Mesbah M.
Stat Med. 2007 Nov 30;26(27):4889-904.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on